Healthcare Industry News: Indevus Pharmaceuticals
News Release - July 11, 2017
Portal Instruments Appoints Wendy Dwyer as Chief Business OfficerCAMBRIDGE, Mass., July 11, 2017 -- (Healthcare Sales & Marketing Network) -- Portal Instruments announced today the appointment of Wendy Dwyer as Chief Business Officer, effective July 6, 2017. Ms. Dwyer will oversee all strategic and business partnerships and report directly to Patrick Anquetil, CEO of Portal Instruments.
Dwyer joins Portal from Ipsen BioScience where, as vice president of corporate development, she built synergistic relationships for the company's US portfolio as well as the neurology franchise. Prior to Ipsen BioScience, Dwyer was in business development with AztraZeneca, securing partnerships for the company's infectious disease and oncology teams. She brings to Portal more than 18 years of experience in business development, having spent 10 of those years with Indevus Pharmaceuticals where she grew partnerships on the buy- and sell-side as well as through M&A activity across a variety of therapeutic areas including urology, endocrinology, oncology, and CNS. She served as vice president of business development upon the acquisition of Indevus by Endo Pharmaceuticals, focusing on the company's urology, endocrinology, and pain therapeutic areas.
Dwyer received a Master of Science Management in Business Administration from Lesley University in Cambridge, Massachusetts and a Bachelor of Science in Psychology from Endicott College in Beverly, Massachusetts.
"I am excited about the road ahead for Portal, recognizing the important and valuable achievements in this unique drug delivery platform and the opportunities to forge strategic industry partnerships to improve the patient experience," said Ms. Dwyer. "I am delighted to join such a committed and motivated team and look forward to helping in the continued growth of Portal."
Portal Instruments is a clinical stage medical device company based in Cambridge, MA. The Portal drug delivery technology is needle-free, fast and computer-controlled. It automatically adjusts the injection velocity up to one thousand times in the half-second it takes to completely deliver a 1 ml dose. The result is the precise administration of high viscosity biologic drugs through the skin, via an extremely collimated jet, the size of a strand of hair. The patient experience can be augmented with HIPPA-compliant, automatic collection and transfer of injection and health data, setting a new standard of engagement between the care team and the patient. With a clear view of patient behavior, protocols can be better managed, research is better informed and compliance is improved.
About Portal Instruments
Portal Instruments is a Series B funded, clinical stage medical device company focused on advanced drug delivery and backed by strategic and venture investors. Portal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for chronic diseases. Portal's needle-free delivery technology is derived from research at MIT and enables the administration of high viscosity biologic drugs with less discomfort and without the anxiety of handling needles. Real time tracking and reporting sets a new standard for interactivity between the patient and care teams, monitoring adherence and potentially improving patient outcomes. Portal Instruments is ISO 13485:2012 certified. For more information, please visit: www.portalinstruments.com or follow @portalcambridge on Twitter.
Source: Portal Instruments
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.